经典血友病患者全髋关节置换术:90天结局与5年假体生存率的匹配比较
基于PearlDiver MHip数据库2010-2020年的回顾性研究,将518例经典血友病全髋关节置换术患者与5193例非血友病患者按1:10匹配。血友病患者90天任何不良事件、严重不良事件和轻微不良事件的风险均更高,出血和静脉血栓栓塞风险增加,5年假体生存率较低(91.9% vs 95.3%),但绝对差异仅3.4%,提示全髋关节置换术在该人群中仍有效。
要点
- 经典血友病患者全髋关节置换术后90天任何不良事件风险增加(OR 1.76),严重不良事件风险增加(OR 2.30)。
- 血友病患者出血相关事件风险更高:输血OR 1.98,血肿OR 4.23;静脉血栓栓塞风险也增加:深静脉血栓OR 2.67,肺栓塞OR 4.01。
- 5年假体生存率血友病患者为91.9%,匹配对照为95.3%(P = .009),绝对差异3.4%,提示全髋关节置换术仍有效。
核心结论
- 经典血友病患者行全髋关节置换术后90天出血并发症(输血和血肿)及静脉血栓栓塞(深静脉血栓和肺栓塞)风险相对匹配对照升高。
- 这些发现强调需要平衡因子替代治疗与静脉血栓栓塞预防。
- 尽管血友病患者5年假体生存率较低,但5年时差异为3.4%,提示全髋关节置换术在该队列中仍然有效。
研究设计与样本
- 回顾性研究,使用2010-2020年PearlDiver MHip数据库。
- 识别接受初次全髋关节置换术的患者,将经典血友病患者按年龄、性别和Elixhauser合并症指数与非血友病患者进行1:10匹配。
- 采用多因素分析比较90天严重不良事件、轻微不良事件和任何不良事件,采用Kaplan-Meier分析评估5年再手术。
主要发现
- 518例经典血友病全髋关节置换术患者与5193例非血友病患者按1:10匹配。
- 多因素分析显示,经典血友病患者任何不良事件聚合的比值比(OR)为1.76,严重不良事件OR为2.30,轻微不良事件OR为1.52(每项P < .001)。
- 经典血友病患者出血问题风险更高:输血OR 1.98,血肿OR 4.23(两项P < .001);静脉血栓栓塞风险更高:深静脉血栓OR 2.67,肺栓塞OR 4.01(两项P < .001);急性肾损伤OR 1.63(P = .03)。
- 5年假体生存率血友病患者为91.9%,匹配对照为95.3%(P = .009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with classic hemophilia can develop joint hemarthroses, degenerative changes, and eventually require total hip arthroplasty (THA). Little data exist concerning THA outcomes in this population, and evidence-based guidelines specifically addressing venous thromboembolism (VTE) prophylaxis in this population are lacking. METHODS: A retrospective study was conducted using the 2010-2020 PearlDiver MHip database. Patients undergoing primary THA were identified, and those with classic hemophilia were matched 1:10 with non-hemophilia patients based on age, gender, and Elixhauser Comorbidity Index. Ninety-day serious adverse events, minor adverse events, and any adverse events were compared with multivariate analysis. Reoperation at 5 years was assessed using Kaplan-Meier analysis. RESULTS: Five hundred eighteen classic hemophilia THA patients were matched 1:10 with 5,193 non-hemophilia patients. On multivariate analysis, those with classic hemophilia had greater odds of aggregated any adverse events (odds ratio [OR] 1.76), serious adverse events (OR 2.30), and minor adverse events (OR 1.52) (P < .001 for each). Patients with classic hemophilia had greater odds of bleeding issues (transfusion, OR 1.98; hematoma, OR 4.23; P < .001 for both), VTE (deep vein thrombosis, OR 2.67; pulmonary embolism, OR 4.01; P < .001 for both), and acute kidney injury (OR 1.63; P = .03). Five-year implant survival was lower in hemophilia patients (91.9%) relative to matched controls (95.3%; P = .009). CONCLUSION: Hemophilia patients undergoing THA had elevated risks of both 90-day bleeding complications (transfusion and hematoma) and VTE (deep vein thrombosis and pulmonary embolism) relative to matched controls. These findings emphasize the need to balance factor replacement and VTE prophylaxis. Although the 5-year implant survival was lower in hemophilia patients, this represented a difference of 3.4% at 5 years, suggesting that THA remains effective in this cohort.
引用
- Gillinov SM, Burroughs PJ, Moore HG, et al. Total Hip Arthroplasty in Patients With Classic Hemophilia: A Matched Comparison of 90-Day Outcomes and 5-Year Implant Survival. J Arthroplasty. 2022. PMID: 35257821. doi:10.1016/j.arth.2022.02.107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。